The estimated Net Worth of James R Meyers is at least $341 mil dollars as of 16 January 2018. Mr. Meyers owns over 100,000 units of Sangamo Therapeutics Inc stock worth over $86,281 and over the last 18 years he sold SGMO stock worth over $0. In addition, he makes $254,758 as Independent Director at Sangamo Therapeutics Inc.
Sign up
Mr. Meyers SGMO stock SEC Form 4 insiders trading
James has made over 6 trades of the Sangamo Therapeutics Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 100,000 units of SGMO stock worth $2,158,000 on 16 January 2018.
The largest trade he's ever made was exercising 100,000 units of Sangamo Therapeutics Inc stock on 16 January 2018 worth over $2,158,000. On average, James trades about 4,745 units every 105 days since 2007. As of 16 January 2018 he still owns at least 102,715 units of Sangamo Therapeutics Inc stock.
You can see the complete history of Mr. Meyers stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Meyers biography
James R. Meyers serves as Independent Director of the Company. He has over 30 years of commercial leadership experience in the biotechnology industry. Mr. Meyers worked at Gilead Sciences, Inc., or Gilead, from 1996 until his retirement in February 2018. Most recently, he served as Gilead’s Executive Vice President of Worldwide Commercial Operations from November 2016 to February 2018, where he was responsible for global commercial activities, including pricing and market access in North America, Europe, Middle East, Australia and Japan. Mr. Meyers joined Gilead in 1996 where he successfully led several important product launches in the HIV and hepatitis C therapeutic areas. Prior to Gilead, Mr. Meyers held positions of increasing responsibility with Zeneca Pharmaceuticals and Astra USA. He currently serves on the board of directors of two public companies, Arbutus Biopharma Corporation and CytomX Therapeutics, Inc., and he remains an active advisor to several major biopharmaceutical companies. Mr. Meyers holds a B.S. in Economics from Boston College. The Nominating and Corporate Governance Committee and the Board believe that Mr. Meyers’ extensive commercial leadership experience in the biotechnology industry provides valuable operational, commercial assessment and management skills to the Board.
What is the salary of James Meyers?
As the Independent Director of Sangamo Therapeutics Inc, the total compensation of James Meyers at Sangamo Therapeutics Inc is $254,758. There are 7 executives at Sangamo Therapeutics Inc getting paid more, with Alexander Macrae having the highest compensation of $3,986,560.
How old is James Meyers?
James Meyers is 55, he's been the Independent Director of Sangamo Therapeutics Inc since 2019. There are 9 older and 9 younger executives at Sangamo Therapeutics Inc. The oldest executive at Sangamo Therapeutics Inc is H. Stewart Parker, 64, who is the Independent Director.
What's James Meyers's mailing address?
James's mailing address filed with the SEC is C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND, CA, 94084.
Insiders trading at Sangamo Therapeutics Inc
Over the last 24 years, insiders at Sangamo Therapeutics Inc have traded over $87,969,621 worth of Sangamo Therapeutics Inc stock and bought 3,434,008 units worth $48,483,268 . The most active insiders traders include Capital Management, L.P.Ra ..., Le Roy C Kopp y Inc.Biogen Ma Inc. Biogen. On average, Sangamo Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $40,671. The most recent stock trade was executed by Inc.Biogen Ma Inc. Biogen on 26 September 2023, trading 6,000,000 units of SGMO stock currently worth $3,000,000.
What does Sangamo Therapeutics Inc do?
for sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com.
What does Sangamo Therapeutics Inc's logo look like?
Complete history of Mr. Meyers stock trades at Arbutus Biopharma Corp, CytomX Therapeutics Inc, Gilead Sciences y Sangamo Therapeutics Inc
Sangamo Therapeutics Inc executives and stock owners
Sangamo Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Alexander Macrae,
President, Chief Executive Officer, Director -
Sung Lee,
Chief Financial Officer, Executive Vice President -
Gary Loeb,
Executive Vice President, Chief Compliance Officer, General Counsel, Secretary -
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.,
CEO, Pres & Director -
R. Andrew Ramelmeier,
Executive Vice President - Technical Operations -
Dr. R. Andrew Ramelmeier Ph.D.,
Exec. VP of Technical Operations -
D. Mark McClung,
Exec. VP & COO -
James Meyers,
Independent Director -
H. Stewart Parker,
Independent Director -
Joseph Zakrzewski,
Independent Director -
Robert Carey,
Independent Director -
Saira Ramasastry,
Independent Director -
Karen Smith,
Independent Director -
McDavid Stilwell,
IR Contact Officer -
John Markels,
Independent Director -
Kenneth Hillan,
Director -
Prathyusha Duraibabu,
Vice President - Finance -
D. Mark McClung,
Executive Vice President, Chief Business Officer -
Scott B. Willoughby,
Sr. VP, Gen. Counsel & Corp. Sec. -
Prathyusha Duraibabu CPA, M.B.A.,
Sr. VP, CFO & Principal Accounting Officer -
Dr. Jason D. Fontenot Ph.D.,
Sr. VP & Chief Scientific Officer -
Prathyusha Duraibabu,
VP of Fin., Principal Accounting Officer & Principal Financial Officer -
Dr. Duncan McKay,
Sr. VP & GM of Europe -
Heather Erickson,
Chief of Staff -
Dr. Nathalie Dubois-Stringfellow,
Sr. VP of Product Devel. & Management -
Whitney Jones,
Sr. VP & Chief People Officer -
Aron Feingold,
Head of Corp. Communications & Investor Relations Officer -
Dr. Jason Fontenot Ph.D.,
Sr. VP & Chief Scientific Officer -
Stephen George Dilly,
Director -
Paul B Cleveland,
Director -
Henry Ward Wolff,
Director -
Steven J Mento,
Director -
William R Ringo,
Director -
Geoffrey Nichol,
Executive Vice President, R&D -
Curt A. Iii Herberts,
Sr.VP & Chief Business Officer -
Dale G Ando,
VP, Therapeutic Dev. & CMO -
Edward R. Conner,
Sr. VP & Chief Medical Officer -
Thomas G Wiggans,
Director -
William G Gerber,
Director -
Roger Jeffs,
Director -
Heather D Turner,
EVP, General Counsel & Sec. -
Robert J. Schott,
SVP, Head of Development -
Stephane Boissel,
EVP, Corp. Strategy -
Kathy Yi,
EVP & Chief Financial Officer -
Margaret Liu,
Director -
Michael C Wood,
Director -
Greg Zante,
Sr Dir., Finance and Admin -
Le Roy C Kopp,
10% owner -
Edward O Ii Lanphier,
President and CEO -
Jon E M Jacoby,
Director -
Casey C Case,
Vice President, Research -
Peter Bluford,
V.P., Corporate Development -
William J Rutter,
Director -
John William Larson,
Director -
Philip D Gregory,
Vice President, Research -
Capital Management, L.P.Ra ...,
-
David G Ichikawa,
Senior VP, Bus. Dev. -
Jason D. Fontenot,
SVP, Chief Scientific Officer -
Scott B. Willoughby,
SVP, GEN. COUNSEL & SECRETARY -
Inc.Biogen Ma Inc. Biogen,
-
Sandy Macrae,
PRESIDENT, CEO AND DIRECTOR -
Nathalie Dubois Stringfellow,
SVP-CHIEF DEVELOPMENT OFFICER -
Amy Pooler,
VP, HEAD OF RESEARCH -
Courtney Beers,
-
Margaret A Horn,